In vitro and in vivo evaluation of novel anticancer agents in triple negative breast cancer models.

Johnson KP, Yearby LA, Stoute D, Burow ME, Rhodes LV, Gray M, Carriere P, Tilghman SL, McLachlan JA, Ochieng J. In vitro and in vivo evaluation of novel anticancer agents in triple negative breast cancer models. J Health Care Poor Underserved. 2013 Feb; 24(1 Suppl):104-11.

View in: PubMed

subject areas

Animals
Antineoplastic Agents, Phytogenic
Breast Neoplasms
Cell Line, Tumor
Cell Proliferation
Chalcone
Female
Humans
Mice
Mice, SCID
Tumor Burden
Xenograft Model Antitumor Assays

authors with profiles

Josiah Ochieng
KiTani Parker-Lemieux
Syreeta Tilghman

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support